Combination Therapy Better for Elderly With Colorectal Cancer
SAN FRANCISCO (IMNG) - Adding bevacizumab to capecitabine for first-line therapy for elderly patients with metastatic colorectal cancer significantly delayed disease progression and improved treatment... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 7, 2013 Category: Cancer & Oncology Source Type: news
Management of Adverse Events in Patients Receiving Capecitabine, a Case-Based Supplement
ISBN: 978-3-8055-9599-5 (Source: Karger Publishers)
Source: Karger Publishers - February 1, 2013 Category: Databases & Libraries Source Type: news
Combo Therapy Shines in Colon Cancer
SAN FRANCISCO (MedPage Today) -- First-line combination bevacizumab and capecitabine therapy may be an optimal first-line treatment for metastatic colorectal cancer in treatment-naive older patients, researchers reported here. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - January 29, 2013 Category: Consumer Health News Source Type: news
Capecitabine Has Edge in CRT for Pancreatic Ca
SAN FRANCISCO (MedPage Today) -- When paired with chemoradiotherapy, capecitabine offered better survival and toxicity outcomes than gemcitabine in locally advanced pancreatic cancer, researchers reported here. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 28, 2013 Category: Primary Care Source Type: news
Cisplatin-based chemotherapy conferred better outcomes than capecitabine-based regimen
Fan Y. Ann Oncol. 2012;doi:10.1093/annonc/mds603. (Source: HemOncToday.com)
Source: HemOncToday.com - January 28, 2013 Category: Cancer & Oncology Source Type: news
Bevacizumab plus paclitaxel vs. bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: phase III TURANDOT trial interim results
Source: Lancet Oncology
Area: News
Randomised phase 3 trials in metastatic breast cancer have shown that combining bevacizumab with either paclitaxel or capecitabine improves progression-free survival (PFS) and response rate compared with chemotherapy alone but the relative efficacy of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine has not been investigated. These two regimens were thus compared in an open-label, non-inferiority, phase III trial [TURANDOT (capeciTabine and bevacizumab Randomised Against avastiN anD taxOl Trial)].
The trial was designed to answer three main questions:
...
Source: NeLM - News - January 10, 2013 Category: Drugs & Pharmacology Source Type: news
Direct Healthcare Professional Communication: Lapatinib combined with capecitabine has poorer efficacy compared with trastuzumab combined with capecitabine
Source: MHRA, GlaxoSmithKiline (GSK)
Area: News
GSK, in agreement with the European Medicines Agency and the MHRA has issued this communcation following the findings of two recent trials showing a statistically superior efficacy of trastuzumab- as compared with lapatinib-based regimens in certain settings. This effect was particularly pronounced in the patients who had no prior exposure to trastuzumab.
EGF111438/CEREBEL is a phase III trial comparing lapatinib in combination with capecitabine relative to trastuzumab in combination with capecitabine on the incidence of CNS as site of first relapse in women with...
Source: NeLM - News - January 3, 2013 Category: Drugs & Pharmacology Source Type: news
